Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Novel PCSK9 Inhibitors and Other Novel Antidyslipidemic ( For reducing cardiovascular risk) | Physician & Payer Forum | US | 2015
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…
Osteoarthritic Pain – As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? | Decision Base | US/EU5 | 2015
As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? Osteoarthritis (OA) is a tremendously prevalent condition…
Gram-Negative Infections due to Carbapenem-Resistant Organisms | Decision Base | US | 2015
The Alarming Scarcity of Treatment Options for These Pathogens Presents an Attractive Market Opportunity for Novel Antibiotics The carbapenems are a class of potent gram-negative antibiotics…
Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 1 | 2015
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the…
Novel Oral Anticoagulants for Acute Coronary Syndrome, Atrial Fibrillation, and Venous Thromboembolism in the EU5 | Physician & Payer Forum | EU5 | 2015
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…
